Novel Treatments in HER2-Positive Breast Cancer

Supplements And Featured PublicationsTherapeutic Changes in HER2+ Breast Cancer
Volume 1
Issue 1

OncLive interviewed experts on novel treatments in HER2-positive breast cancer. 

OncLive interviewed experts on novel treatments in HER2-positive breast cancer.

Supported by an unrestricted educational grant by Daiichi Sankyo

Articles in this issue
Novel Treatments in HER2-Positive Breast Cancer
Novel Treatments in HER2-Positive Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Thompson on Sequencing Strategies in HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Hurvitz on Treatment Options in Early-Stage HER2+ Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Olajide on Managing Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in Breast Cancer
Dr. Krill-Jackson on the Potential Utility of Trastuzumab Deruxtecan in Metastatic Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Dr. Hurvitz on Additional Research Needed With Trastuzumab Deruxtecan in HER2+ Breast Cancer
Related Videos
Brian Henick, MD
Abhinav Deol, MD
Veronika Bachanova, MD, PhD
Walter M. Stadler, MD
Susan Domchek, MD, FASCO
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Amy L. Cummings, MD, thoracic oncologist, assistant professor of medicine, David Geffen School of Medicine, University of California Los Angeles (UCLA) Jonsson Comprehensive Cancer Center
Expert on CSCC
Expert on CSCC
Related Content

Cleveland Clinic Opens New Cancer Center in Abu Dhabi

March 23rd 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia

March 22nd 2023

Cleveland Clinic Opens New Cancer Center in Abu Dhabi

March 23rd 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia

March 22nd 2023

Cleveland Clinic Opens New Cancer Center in Abu Dhabi

March 23rd 2023

FDA Approval Insights: Sacituzumab Govitecan in HR-positive, HER2-negative Breast Cancer

March 20th 2023

Newly Defined Breast Cancer Targets Expand TNBC Treatment Options

March 23rd 2023

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Spotlight on a Rare Hematologic Disorder: Hereditary Hemorrhagic Telangiectasia

March 22nd 2023